# A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

> **NCT04436744** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 221 (actual)

## Conditions studied

- Early Breast Cancer

## Interventions

- **DRUG:** Giredestrant
- **DRUG:** Anastrozole
- **DRUG:** Palbociclib
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT04436744
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-04
- **Primary completion:** 2021-07-06
- **Final completion:** 2021-11-24
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2023-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04436744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04436744, "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04436744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*